Navigation Links
Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine

Effort is Launched With UC Davis Collaboration

RANCHO CORDOVA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury, today announced a regenerative medicine initiative in the veterinary market.

The Company has created a wholly-owned subsidiary, Vantus, Inc., a veterinary stem cell laboratory services company. The Company is in the process of completing a research collaboration with the Center for Equine Health and Stem Cell Regenerative Medicine Group at the University of California, Davis, School of Veterinary Medicine.

Under the collaboration, the Company's MarrowXpress(TM) System and BioArchive(R) System will be used for the processing and cryogenic storage of equine stem cells from cell rich sources, including fetal tissue and fluids during foaling, and bone marrow from yearlings and adults. The stem cells will be used in therapeutic treatment of orthopedic injuries in the performance equine market including Thoroughbreds, American Quarter Horses, and Arabians. The Company is currently refining collection and processing methodologies at large breeder farms in California, and expects to be in operation commencing with the 2009 foaling season, which begins in January of next year.

"The creation of Vantus, Inc. is a major milestone in our regenerative medicine diversification strategy that we began implementing several months ago. This program leverages the expertise and world renowned reputation of the UC Davis organization in animal research and our industry leading stem cell processing and storage technologies," noted Dr. William Osgood, Chief Executive Officer of ThermoGenesis.

"We have the potential to create a new paradigm for the treatment of injured performance horses using our unique approach of capturing stem cells when the horse is born up through the first year of life. This represents a potentially sizeable market opportunity for the Company in which we believe we can achieve a meaningful competitive advantage quickly. Equine stem cells are being used successfully to treat a number of injuries today, with the potential for significant and rapid growth given the early clinical efficacy of these treatments and relatively low regulatory hurdles in the veterinary market," he added.

"The collaborative support and assistance we will be receiving from Vantus should allow our scientists to move forward rapidly in the development of new and unique veterinary stem cell applications. We expect that their experience in the processing and bioarchival storage of stem cells, combined with the expertise of our research and clinical personnel, will provide compelling synergy for scientific discovery," said Dr. Gregory Ferraro, of the UC Davis Center for Equine Health.

Osgood noted, "In addition, the experience we gain in the veterinary stem cell market and the products and services that will come from research and innovations in harvesting, processing, and therapeutic treatments, will directly translate to treatment of human orthopedic injury and disease and speed our entry into this evolving market."

"Finally, we believe our wound healing technologies will have direct application in the veterinary market, which we expect will add additional revenues to the Company," he added.

To learn more about Vantus please log onto

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by

cord blood stem cell banks in more than 25 countries for cryopreserving

and archiving cord blood stem cell units for transplant. GE Healthcare

is the nonexclusive global distribution partner for the BioArchive


-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of

automated devices that includes the AXP and the MarrowXpress(TM) and

companion sterile blood processing disposable for harvesting stem cells

in a closed system. The AXP device is used for the processing of cord

blood. GE Healthcare is the exclusive global distribution partner for

the AXP cord blood product. The MarrowXpress is used for isolating stem

cells from bone marrow. ThermoGenesis sells the MarrowXpress directly

to global customers.

-- The CryoSeal(R) FS System, an automated device and companion sterile

blood processing disposable, is used to prepare fibrin sealants from

plasma in about an hour. We received FDA approval to market the

CryoSeal FS System in liver resection surgeries in July 2007. The

CryoSeal FS System has received the CE-Mark. From a marketing

perspective, the CE Mark is the European equivalent to an FDA approval,

in that it allows sales of the product throughout the European

community. Asahi Medical is the exclusive distributor for the CryoSeal

System in Japan and the Company markets through independent

distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood

processing disposable that prepares activated thrombin from a small

aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

currently being marketed in Europe by Biomet, Inc., subsidiary Biomet

Biologics, Medtronic, Inc. and independent distributors.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

ThermoGenesis Corp.

Web site:

Contact: Investor Relations

+1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Corp. Reports First Quarter 2008 Results
2. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
3. Zipfizz(R) Announces Expanded Distribution
4. Mangrove Announces Health Savings Account (HSA) and Health Reimbursement Account (HRA) Product Launches
5. Senetek PLC Announces Launch of New Website
6. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
7. Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008
8. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
9. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
10. The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application
11. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... anesthesia and pain management services, today announced its partnership with WPC Healthcare ... data from disparate systems and organizes the data into an aggregated data repository ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take ... and NAVUG Summit are independent user conferences designed and led by users to ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology company ... a significant contract that will provide its award-winning private messaging solution to Independence ... growing success of its Relay program, IBX Wire™, which now has over 550,000 ...
(Date:10/13/2015)... ... 13, 2015 , ... A child without a healthy mouth is much more ... remote invisible aligner system, has joined with Global Dental Relief (GDR) to ... aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a child in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Nordic ... unique health needs of new moms. Postnatal Omega-3, which has been named ... utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. This breakthrough oil combines ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Health Gorilla ( ) today announced the ... a secure platform for clinical data and communications poised to ... manage healthcare in the US. The launch follows the closing ... total of $4.4M raised to date, with Data Collective ... , Harris Barton , Orfin Ventures and ...
(Date:10/13/2015)... --> --> Opportunities for ... Asthma and COPD Therapies market? Which areas are going to ... report shows you potential revenues to 2025, assessing data, trends, ... tables, charts, and graphs. Discover the most lucrative areas in ... lets you assess forecasted sales at overall world market and ...
(Date:10/13/2015)... SPRINGS, N.C. , Oct. 13, 2015  Yesterday ... NVS Influenza Vaccines Holly Springs manufacturing site located in ... Since 2014, the facility has produced Flucelvax ® ... has the potential for faster start-up and is not ... 2015 CSL Limited acquired the influenza vaccines business of ...
Breaking Medicine Technology: